The DowDuPont Specialty Products Division (DuPont) announced May 29 that it is further strengthening its efforts in the nutrition and biosciences field by combining its Nutrition & Health and Industrial Biosciences business divisions into a $6.2 billion business division called Nutrition & Biosciences.
According to the announcement, the new and sizable business will be a global market leader across the fields of specialty food ingredients, dietary supplements, pharma excipients, household and personal care, animal nutrition and biotechnology, with a unique product portfolio and science-based approach creating leading innovations to customers across the globe.
“Both DuPont Nutrition & Health and Industrial Biosciences are known for their innovations and strong scientific approach,” Nutrition & Biosciences president Matthias Heinzel said. “Combining the two businesses is a step to further accelerate growth and innovation while better providing customers across our industries with innovative, healthy, safe and sustainable solutions.”
The new business will, for example, benefit from complementary expertise and skills in the areas of food enzyme production, human and animal microbiome science, bioprocess engineering and research and development (R&D), DuPont said. Moreover, a new business structure will ensure a more targeted go-to-market strategy.
DuPont Nutrition & Biosciences will serve customers through three market-driven platforms: Food & Beverage, Health & Bioscience and Pharma Solutions. These focused platforms will better serve customers in the specialty food, health care, pharma, household and personal care, animal nutrition and biotech sectors with a clear end-market customer approach, the company said.
The business platforms will have a distinct positioning in the market that will enhance market visibility, insights, customer intimacy and drive overall business growth.
The new Nutrition & Biosciences business will be led by Heinzel with headquarters in Copenhagen, Denmark. After combining, the new Nutrition & Biosciences business reported 2018 revenue of $6.2 billion, with more than 10,000 employees, 70 manufacturing sites and 25 innovation centers across the globe.